Regeneron(REGN)
Focus: Regeneron is a large-cap, publicly traded biopharmaceutical company headquartered in Tarrytown, NY with 13,000 employees specializing in biologics and small molecules across ophthalmology, oncology, immunology, and rare diseases. The company generates $13.1B in annual revenue with significant profitability.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
13,000
Open Jobs
427+25 this month
Hot — 140 jobs added in 30d
Net +25 (140 new, 115 removed). Aggressive expansion phase.
Should You Work at Regeneron?
AI assessmentRegeneron offers exceptional stability and scale for commercial and clinical career paths, but career longevity depends critically on maintaining EYLEA dominance and successfully advancing oncology/immunology pipeline.
Why Work Here
- Dominant position in ophthalmology with EYLEA generating $74M in Part D spending and driving 85% of revenue, providing stable platform for career growth
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$13.1B
Key Products
$74M Part DStable
Peak
Flagship product representing 85% of company revenue; EYLEA HD variant in growth phase indicates formulation innovation to extend market exclusivity.
Help build intelligence for Regeneron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.